|
|
|
 |
FDA Approval Activities for this Drug…
Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S006 8/6/03 8/15/03 8/15/03 | Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S005 8/5/03 8/15/03 8/6/03 | Relenza (zanamivir for inhalation), 5 mg, Glaxo Wellcome, 21-036/S004 4/27/01 05/08/03 | Relenza (zanamivir for inhalation),5 mg, Patient Label Glaxo Wellcome, 21-036/S001 4/26/00 4/27/00 4/27/00 | Relenza (zanamivir for inhalation) GlaxoWellcome NDA 21-036 7/26/99 12/30/99 7/27/99 12/27/99 | Relenza Indication: For the treatment of uncomplicated acute illness due to influenza virus in adults and adolescents twelve years and older who have been symptomatic for no more than two days. | RELENZA (zanamivir) inhalation, GlaxoSmithKline, New or Modified Indication | RELENZA (zanamivir) Inhalation, GlaxoSmithKline, Labeling Revision | RELENZA (zanamivir) Inhalation, GlaxoSmithKline, Labeling Revision | RELENZA (zanamivir) Inhalation Powder, GlaxoSmithKline, Labeling Revision | Relenza (zanamivir) Inhalation Powder, GlaxoSmithKline, Labeling Revision | Relenza (zanamivir) Inhalation Powder, GlaxoSmithKline, Labeling Revision | Relenza (zanamivir) Inhalation Powder, GlaxoSmithKline, Labeling Revision | Relenza (zanamivir) Inhalation Powder, GlaxoSmithKline, Labeling Revision | Relenza, zanamivir, Powder; Inhalation, Glaxosmithkline, Labeling Revision
  
|